Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience.
C-peptide
GLP1RA
SGLT2i
Type 2 diabetes
insulin therapy
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
01
2022
accepted:
11
05
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
We evaluated the clinical impact, in daily clinical practice, of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) therapies in patients with type 2 diabetes. Data from 500 unselected consecutive patients were retrospectively analyzed. Only those with a full assessment at baseline (T0) and after 3 (T3), 6 (T6), and 12 (T12) months of treatment with SGLT2i or GLP1RA were included in the study (
Identifiants
pubmed: 35859794
doi: 10.1515/med-2022-0504
pii: med-2022-0504
pmc: PMC9263895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1203-1215Informations de copyright
© 2022 Giuseppina Piazzolla et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare that they have no actual or potential conflict of interest in relation to this work.
Références
J Clin Invest. 1987 May;79(5):1510-5
pubmed: 3571496
Int J Mol Sci. 2020 Oct 22;21(21):
pubmed: 33105763
J Am Coll Cardiol. 2020 Aug 4;76(5):580-589
pubmed: 32731936
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Diabetes Metab Syndr Obes. 2021 Aug 10;14:3567-3602
pubmed: 34413662
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Diabetes Metab Syndr Obes. 2021 Aug 05;14:3517-3521
pubmed: 34385826
Diabetes Obes Metab. 2016 Aug;18(8):783-94
pubmed: 27059700
Rev Endocr Metab Disord. 2014 Sep;15(3):181-7
pubmed: 24811133
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Life Sci. 2020 Jan 1;240:117090
pubmed: 31765648
Endocrinol Diabetes Metab. 2020 Jun 11;3(3):e00163
pubmed: 32704576
J Vasc Surg. 2019 Aug;70(2):607-614.e3
pubmed: 30878256
Minerva Endocrinol. 2018 Sep;43(3):229-235
pubmed: 28001016
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 31665455
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
J Oncol Pharm Pract. 2022 Jun;28(4):870-883
pubmed: 33847190
Diabetol Metab Syndr. 2019 Oct 26;11:87
pubmed: 31673296
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
PLoS One. 2017 Oct 24;12(10):e0186708
pubmed: 29065130
Diabetologia. 2020 Feb;63(2):221-228
pubmed: 31853556
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617
pubmed: 31196815
Hosp Pract (1995). 2020 Mar 14;48(2):68-74
pubmed: 32098545
Circulation. 2021 Feb 2;143(5):438-448
pubmed: 33186054
Curr Vasc Pharmacol. 2020;18(2):172-181
pubmed: 30961499
Ann Pharmacother. 2021 Jan;55(1):65-79
pubmed: 32571083
N Engl J Med. 2021 Mar 25;384(12):1113-1124
pubmed: 33185364
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Obes Rev. 2019 Jun;20(6):816-828
pubmed: 30972878
Lancet Diabetes Endocrinol. 2021 Jan;9(1):46-52
pubmed: 33159841
BMJ Open Diabetes Res Care. 2019 Oct 25;7(1):e000783
pubmed: 31749970
BMJ. 2021 Jan 13;372:m4573
pubmed: 33441402